Sayo Horibe
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Sayo Horibe has a total of 47 co-authors. Here are the top co-authors by number of shared publications:
- Yoshiyuki Rikitake
Laboratory of Medical Pharmaceutics, Kobe Pharmaceutical University
7 shared publications - Naoto Sasaki
Laboratory of Medical Pharmaceutics, Kobe Pharmaceutical University, Kobe, Japan
4 shared publications - Aga Krisnanda
Interactive Research & Development, Jakarta, Indonesia
3 shared publications Naoto Sasaki
Laboratory of Medical Pharmaceutics, Kobe Pharmaceutical University, Kobe 658-8558, Japan
3 shared publicationsShoji Kawauchi
Laboratory of Pharmacy Practice, Kobe Pharmaceutical University, Kobe 658-8558, Japan
3 shared publications- Shoji Kawauchi
Laboratory of Pharmacy Practice, Comprehensive Education and Research Center, Kobe Pharmaceutical University, Kobe, Japan
3 shared publications
Latest Publications
- Open Access
- 18 April 2026
- Published by Elsevier in Photodiagnosis and Photodynamic Therapy
- Vol. 59, 105487
Enhanced accumulation of protoporphyrin IX via SLC6A6 and SLC36A1 sensitizes cisplatin-resistant cells to 5-aminolevulinic acid-based photodynamic therapy
- 18 April 2026
- Published by Elsevier in Photodiagnosis and Photodynamic Therapy
- Vol. 59, 105487
Open AccessEnhanced accumulation of protoporphyrin IX via SLC6A6 and SLC36A1 sensitizes cisplatin-resistant cells to 5-aminolevulinic acid-based photodynamic therapy
- Open Access
- 17 March 2026
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 15 (6) , e043202
C‐C Chemokine Receptor 4 Deficiency Protects Against Abdominal Aortic Aneurysm Formation
Background: The dysregulated immune system, which drives chronic vascular inflammation and remodeling, plays a critical role in the pathogenesis of abdominal aortic aneurysm (AAA). CCR4 (C‐C chemokine receptor 4), which is predominantly expressed on T cells and mediates their responses, has been shown to protect against inflammatory diseases including atherosclerosis. However, its role in AAA remains unknown. Methods: By analyzing hypercholesterolemic CCR4‐deficient ( Ccr4 −/− ) mice on an apolipoprotein E‐deficient ( Apoe −/− ) background, we investigated the role of CCR4 in the development of angiotensin II‐induced AAA, with a particular focus on T‐cell‐mediated immune responses, by performing histological analysis, flow cytometry, biochemical assays, and single‐cell RNA sequencing analysis. Results: Genetic deletion of CCR4 on an Apoe −/− background dramatically reduced the incidence and severity of angiotensin II‐induced AAA without affecting mortality due to rupture, along with attenuated inflammatory cell recruitment and preserved elastic lamellae in the aorta. This protective effect was associated with a shift in the T helper cell balance toward T helper type 1 predominance, characterized by promoted IFN‐γ (interferon‐gamma) production and suppressed B‐cell‐mediated IgE production. Single‐cell RNA sequencing analysis of abdominal aortic tissues revealed lower proportions of myofibroblasts and modulated smooth muscle cells highly expressing genes associated with extracellular matrix remodeling in angiotensin II‐infused Ccr4 −/− Apoe −/− mice, potentially driven by downregulated TGF‐β (transforming growth factor‐beta) signaling due to increased T helper type 1 cell‐derived IFN‐γ. Conclusions: CCR4 may serve as a potential therapeutic target for AAA.
- 17 March 2026
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 15 (6) , e043202
Open AccessC‐C Chemokine Receptor 4 Deficiency Protects Against Abdominal Aortic Aneurysm Formation
Background: The dysregulated immune system, which drives chronic vascular inflammation and remodeling, plays a critical role in the pathogenesis of abdominal aortic aneurysm (AAA). CCR4 (C‐C chemokine receptor 4), which is predominantly expressed on T cells and mediates their responses, has been shown to protect against inflammatory diseases including atherosclerosis. However, its role in AAA remains unknown. Methods: By analyzing hypercholesterolemic CCR4‐deficient ( Ccr4 −/− ) mice on an apolipoprotein E‐deficient ( Apoe −/− ) background, we investigated the role of CCR4 in the development of angiotensin II‐induced AAA, with a particular focus on T‐cell‐mediated immune responses, by performing histological analysis, flow cytometry, biochemical assays, and single‐cell RNA sequencing analysis. Results: Genetic deletion of CCR4 on an Apoe −/− background dramatically reduced the incidence and severity of angiotensin II‐induced AAA without affecting mortality due to rupture, along with attenuated inflammatory cell recruitment and preserved elastic lamellae in the aorta. This protective effect was associated with a shift in the T helper cell balance toward T helper type 1 predominance, characterized by promoted IFN‐γ (interferon‐gamma) production and suppressed B‐cell‐mediated IgE production. Single‐cell RNA sequencing analysis of abdominal aortic tissues revealed lower proportions of myofibroblasts and modulated smooth muscle cells highly expressing genes associated with extracellular matrix remodeling in angiotensin II‐infused Ccr4 −/− Apoe −/− mice, potentially driven by downregulated TGF‐β (transforming growth factor‐beta) signaling due to increased T helper type 1 cell‐derived IFN‐γ. Conclusions: CCR4 may serve as a potential therapeutic target for AAA.
- Open Access
- 3 July 2025
- Published by eLife Sciences Publications, Ltd in eLife
- Vol. 13
C-C chemokine receptor 4 deficiency exacerbates early atherosclerosis in mice
Chronic inflammation via dysregulation of T cell immune responses is critically involved in the pathogenesis of atherosclerotic cardiovascular disease. Improving the balance between proinflammatory T cells and anti-inflammatory regulatory T cells (Tregs) may be an attractive approach for treating atherosclerosis. Although C-C chemokine receptor 4 (CCR4) has been shown to mediate the recruitment of T cells to inflamed tissues, its role in atherosclerosis is unclear. Here, we show that genetic deletion of CCR4 in hypercholesterolemic mice accelerates the development of early atherosclerotic lesions characterized by an inflammatory plaque phenotype. This was associated with the augmentation of proinflammatory T helper type 1 (Th1) cell responses in peripheral lymphoid tissues, para-aortic lymph nodes, and atherosclerotic aorta. Mechanistically, CCR4 deficiency in Tregs impaired their suppressive function and tended to inhibit their migration to the atherosclerotic aorta, and subsequently augmented Th1 cell-mediated immune responses through defective regulation of dendritic cell function, which accelerated aortic inflammation and atherosclerotic lesion development. Thus, we revealed a previously unrecognized role for CCR4 in controlling the early stage of atherosclerosis via Treg-dependent regulation of proinflammatory T cell responses. Our data suggest that CCR4 is an important negative regulator of atherosclerosis.
- 3 July 2025
- Published by eLife Sciences Publications, Ltd in eLife
- Vol. 13
Open AccessC-C chemokine receptor 4 deficiency exacerbates early atherosclerosis in mice
Chronic inflammation via dysregulation of T cell immune responses is critically involved in the pathogenesis of atherosclerotic cardiovascular disease. Improving the balance between proinflammatory T cells and anti-inflammatory regulatory T cells (Tregs) may be an attractive approach for treating atherosclerosis. Although C-C chemokine receptor 4 (CCR4) has been shown to mediate the recruitment of T cells to inflamed tissues, its role in atherosclerosis is unclear. Here, we show that genetic deletion of CCR4 in hypercholesterolemic mice accelerates the development of early atherosclerotic lesions characterized by an inflammatory plaque phenotype. This was associated with the augmentation of proinflammatory T helper type 1 (Th1) cell responses in peripheral lymphoid tissues, para-aortic lymph nodes, and atherosclerotic aorta. Mechanistically, CCR4 deficiency in Tregs impaired their suppressive function and tended to inhibit their migration to the atherosclerotic aorta, and subsequently augmented Th1 cell-mediated immune responses through defective regulation of dendritic cell function, which accelerated aortic inflammation and atherosclerotic lesion development. Thus, we revealed a previously unrecognized role for CCR4 in controlling the early stage of atherosclerosis via Treg-dependent regulation of proinflammatory T cell responses. Our data suggest that CCR4 is an important negative regulator of atherosclerosis.
- Open Access
- 16 January 2024
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 13 (2) , e031639
Novel UV‐B Phototherapy With a Light‐Emitting Diode Device Prevents Atherosclerosis by Augmenting Regulatory T‐Cell Responses in Mice
Background: Ultraviolet B (UV‐B) irradiation is an effective treatment for human cutaneous disorders and was shown to reduce experimental atherosclerosis by attenuating immunoinflammatory responses. The aim of this study was to clarify the effect of specific wavelengths of UV‐B on atherosclerosis and the underlying mechanisms focusing on immunoinflammatory responses. Methods and Results: Based on light‐emitting diode technology, we developed novel devices that can emit 282 nm UV‐B, which we do not receive from natural sunlight, 301 nm UV‐B, and clinically available 312 nm UV‐B. We irradiated 6‐week‐old male atherosclerosis‐prone Apoe −/− (apolipoprotein E‐deficient) mice with specific wavelengths of UV‐B and evaluated atherosclerosis and immunoinflammatory responses by performing histological analysis, flow cytometry, biochemical assays, and liquid chromatography/mass spectrometry‐based lipidomics. Irradiation of 282 nm UV‐B but not 301 or 312 nm UV‐B significantly reduced the development of aortic root atherosclerotic plaques and plaque inflammation. This atheroprotection was associated with specifically augmented immune responses of anti‐inflammatory CD4 + Foxp3 (forkhead box P3) + regulatory T cells in lymphoid tissues, whereas responses of other immune cells were not substantially affected. Analysis of various lipid mediators revealed that 282 nm UV‐B markedly increased the ratio of proresolving to proinflammatory lipid mediators in the skin. Conclusions: We demonstrated that 282 nm UV‐B irradiation effectively reduces aortic inflammation and the development of atherosclerosis by systemically augmenting regulatory T‐cell responses and modulating the balance between proresolving and proinflammatory lipid mediators in the skin. Our findings indicate that a novel 282 nm UV‐B phototherapy could be an attractive approach to treat atherosclerosis.
- 16 January 2024
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 13 (2) , e031639
Open AccessNovel UV‐B Phototherapy With a Light‐Emitting Diode Device Prevents Atherosclerosis by Augmenting Regulatory T‐Cell Responses in Mice
Background: Ultraviolet B (UV‐B) irradiation is an effective treatment for human cutaneous disorders and was shown to reduce experimental atherosclerosis by attenuating immunoinflammatory responses. The aim of this study was to clarify the effect of specific wavelengths of UV‐B on atherosclerosis and the underlying mechanisms focusing on immunoinflammatory responses. Methods and Results: Based on light‐emitting diode technology, we developed novel devices that can emit 282 nm UV‐B, which we do not receive from natural sunlight, 301 nm UV‐B, and clinically available 312 nm UV‐B. We irradiated 6‐week‐old male atherosclerosis‐prone Apoe −/− (apolipoprotein E‐deficient) mice with specific wavelengths of UV‐B and evaluated atherosclerosis and immunoinflammatory responses by performing histological analysis, flow cytometry, biochemical assays, and liquid chromatography/mass spectrometry‐based lipidomics. Irradiation of 282 nm UV‐B but not 301 or 312 nm UV‐B significantly reduced the development of aortic root atherosclerotic plaques and plaque inflammation. This atheroprotection was associated with specifically augmented immune responses of anti‐inflammatory CD4 + Foxp3 (forkhead box P3) + regulatory T cells in lymphoid tissues, whereas responses of other immune cells were not substantially affected. Analysis of various lipid mediators revealed that 282 nm UV‐B markedly increased the ratio of proresolving to proinflammatory lipid mediators in the skin. Conclusions: We demonstrated that 282 nm UV‐B irradiation effectively reduces aortic inflammation and the development of atherosclerosis by systemically augmenting regulatory T‐cell responses and modulating the balance between proresolving and proinflammatory lipid mediators in the skin. Our findings indicate that a novel 282 nm UV‐B phototherapy could be an attractive approach to treat atherosclerosis.
- Open Access
- 20 December 2021
- Published by Spandidos Publications in Oncology Reports
- Vol. 47 (2) , 1-12
Mitochondrial DNA mutations are involved in the acquisition of cisplatin resistance in human lung cancer A549 cells
The efficacy of cisplatin (CDDP) has been demonstrated in the treatment of various cancers as monotherapy and combination therapy with immunotherapy. However, acquired CDDP resistance is a major obstacle to successful treatment. In the present study, the mechanisms underlying acquired CDDP resistance were examined using ACR20 cells, which are CDDP‑resistant cells derived from A549 lung cancer cells. CDDP induces cytotoxicity by binding nuclear DNA and generating reactive oxygen species (ROS). Contrary to our expectation, ROS levels were elevated in ACR20 cells not treated with CDDP. Pretreatment with an ROS inhibitor enhanced the sensitivity of ACR20 cells to CDDP and prevented the activation of nuclear factor (NF)‑кB signaling and upregulation of inhibitor of apoptosis proteins (IAPs). Notably, evaluation of the mitochondrial oxygen consumption rate and mitochondrial superoxide levels revealed a deterioration of mitochondrial function in ACR20 cells. Mitochondrial DNA PCR‑RFLP analysis revealed four mutations with varying percentage levels in ACR20 cells. In addition, in cytoplasmic hybrids with mitochondria from ACR20 cells, intrinsic ROS levels were elevated, expression of IAPs was increased, and complex I activity and sensitivity to CDDP were decreased. Analysis of three‑dimensional structure data indicated that a mutation (ND2 F40L) may impact the proton translocation pathway, thereby affecting mitochondrial complex I activity. Together, these findings suggest that intrinsic ROS levels were elevated by mitochondrial DNA mutations, which decreased the sensitivity to CDDP via activation of NF‑κB signaling and induction of IAP expression in ACR20 cells. These findings indicate that newly identified mutations in mitochondrial DNA may lead to acquired cisplatin resistance in cancer.
- 20 December 2021
- Published by Spandidos Publications in Oncology Reports
- Vol. 47 (2) , 1-12
Open AccessMitochondrial DNA mutations are involved in the acquisition of cisplatin resistance in human lung cancer A549 cells
The efficacy of cisplatin (CDDP) has been demonstrated in the treatment of various cancers as monotherapy and combination therapy with immunotherapy. However, acquired CDDP resistance is a major obstacle to successful treatment. In the present study, the mechanisms underlying acquired CDDP resistance were examined using ACR20 cells, which are CDDP‑resistant cells derived from A549 lung cancer cells. CDDP induces cytotoxicity by binding nuclear DNA and generating reactive oxygen species (ROS). Contrary to our expectation, ROS levels were elevated in ACR20 cells not treated with CDDP. Pretreatment with an ROS inhibitor enhanced the sensitivity of ACR20 cells to CDDP and prevented the activation of nuclear factor (NF)‑кB signaling and upregulation of inhibitor of apoptosis proteins (IAPs). Notably, evaluation of the mitochondrial oxygen consumption rate and mitochondrial superoxide levels revealed a deterioration of mitochondrial function in ACR20 cells. Mitochondrial DNA PCR‑RFLP analysis revealed four mutations with varying percentage levels in ACR20 cells. In addition, in cytoplasmic hybrids with mitochondria from ACR20 cells, intrinsic ROS levels were elevated, expression of IAPs was increased, and complex I activity and sensitivity to CDDP were decreased. Analysis of three‑dimensional structure data indicated that a mutation (ND2 F40L) may impact the proton translocation pathway, thereby affecting mitochondrial complex I activity. Together, these findings suggest that intrinsic ROS levels were elevated by mitochondrial DNA mutations, which decreased the sensitivity to CDDP via activation of NF‑κB signaling and induction of IAP expression in ACR20 cells. These findings indicate that newly identified mutations in mitochondrial DNA may lead to acquired cisplatin resistance in cancer.
- Open Access
- 9 February 2019
- Published by MDPI AG in Marine Drugs
- Vol. 17 (2) , 104
Inhibitory Effects of Sodium Alginate on Hepatic Steatosis in Mice Induced by a Methionine- and Choline-Deficient Diet
Nonalcoholic steatohepatitis (NASH) progresses from nonalcoholic fatty liver disease (NAFLD); however, efficacious drugs for NASH treatment are lacking. Sodium alginate (SA), a soluble dietary fiber extracted from brown algae, could protect the small intestine from enterobacterial invasion. NASH pathogenesis has been suggested to be associated with enterobacterial invasion, so we examined the effect of SA on methionine- and choline-deficient (MCD) diet-induced steatohepatitis in mice (the most widely-used model of NASH). The mice (n = 31) were divided into three groups (mice fed with regular chow, MCD diet, and MCD diet premixed with 5% SA) for 4 and 8 weeks. The MCD diet increased lipid accumulation and inflammation in the liver, the NAFLD Activity Score and hepatic mRNA expression of tumor necrosis factor-α and collagen 1α1, and induced macrophage infiltration. Villus shortening, disruption of zonula occludens-1 localization and depletion of mucus production were observed in the small intestine of the MCD-group mice. SA administration improved lipid accumulation and inflammation in the liver, and impaired barrier function in the small intestine. Collectively, these results suggest that SA is useful for NASH treatment because it can prevent hepatic inflammation and fatty degeneration by maintaining intestinal barrier function.
- 9 February 2019
- Published by MDPI AG in Marine Drugs
- Vol. 17 (2) , 104
Open AccessInhibitory Effects of Sodium Alginate on Hepatic Steatosis in Mice Induced by a Methionine- and Choline-Deficient Diet
Nonalcoholic steatohepatitis (NASH) progresses from nonalcoholic fatty liver disease (NAFLD); however, efficacious drugs for NASH treatment are lacking. Sodium alginate (SA), a soluble dietary fiber extracted from brown algae, could protect the small intestine from enterobacterial invasion. NASH pathogenesis has been suggested to be associated with enterobacterial invasion, so we examined the effect of SA on methionine- and choline-deficient (MCD) diet-induced steatohepatitis in mice (the most widely-used model of NASH). The mice (n = 31) were divided into three groups (mice fed with regular chow, MCD diet, and MCD diet premixed with 5% SA) for 4 and 8 weeks. The MCD diet increased lipid accumulation and inflammation in the liver, the NAFLD Activity Score and hepatic mRNA expression of tumor necrosis factor-α and collagen 1α1, and induced macrophage infiltration. Villus shortening, disruption of zonula occludens-1 localization and depletion of mucus production were observed in the small intestine of the MCD-group mice. SA administration improved lipid accumulation and inflammation in the liver, and impaired barrier function in the small intestine. Collectively, these results suggest that SA is useful for NASH treatment because it can prevent hepatic inflammation and fatty degeneration by maintaining intestinal barrier function.
- 1 December 2018
- Published by Elsevier in Biochemical and Biophysical Research Communications
- Vol. 507 (1-4) , 426-432
CD44v-dependent upregulation of xCT is involved in the acquisition of cisplatin-resistance in human lung cancer A549 cells
- 1 December 2018
- Published by Elsevier in Biochemical and Biophysical Research Communications
- Vol. 507 (1-4) , 426-432
CD44v-dependent upregulation of xCT is involved in the acquisition of cisplatin-resistance in human lung cancer A549 cells
- Open Access
- 6 January 2018
- Published by Springer Nature in BMC Cancer
- Vol. 18 (1) , 1-9
Mechanism of recipient cell-dependent differences in exosome uptake
Exosomes, small-membrane vesicles, are secreted by cells and include several types of proteins and nucleic acids. Exosomes transfer cellular information derived from donor cells and are involved in various physiological and pathological events, such as organ-specific metastasis. Elucidating the exosome uptake mechanisms is important for understanding the progression processes of organ-specific metastasis. However, whether the exosomes secreted by the donor cells are selectively or non-selectively incorporated into the recipient cells is unknown. In this study, three human carcinoma cell lines, A549 (lung), HCT116 and COLO205 (colon), were used. The exosome isolation efficiency was compared between three methods: ultracentrifugation, ExoQuick-TC and Total Exosome Isolation kits. Recipient cells were treated with Pitstop 2, an inhibitor of clathrin-dependent endocytosis, or genistein, an inhibitor of caveolae-dependent endocytosis, and then incubated with DiO-labeled exosomes. Among the three methods examined, ultracentrifugation was the most efficient and reproducible. Exosomes derived from a donor cell line are incorporated into the three cell lines, but the exosome uptake capability was different depending on the recipient cell type and did not depend on the donor cell type. Exosome uptake in COLO205 was inhibited by Pitstop 2 and genistein. Exosome uptake in HCT116 was inhibited by Pitstop 2, but not genistein, while that in A549 cells was not inhibited by these inhibitors. Taken together, these results suggest that the exosomes secreted by donor cells are non-selectively incorporated into recipient cells and that the exosome uptake mechanism is different depending on the recipient cells. Different recipient cells’ exosome uptake capabilities may be involved in organ-specific metastasis.
- 6 January 2018
- Published by Springer Nature in BMC Cancer
- Vol. 18 (1) , 1-9
Open AccessMechanism of recipient cell-dependent differences in exosome uptake
Exosomes, small-membrane vesicles, are secreted by cells and include several types of proteins and nucleic acids. Exosomes transfer cellular information derived from donor cells and are involved in various physiological and pathological events, such as organ-specific metastasis. Elucidating the exosome uptake mechanisms is important for understanding the progression processes of organ-specific metastasis. However, whether the exosomes secreted by the donor cells are selectively or non-selectively incorporated into the recipient cells is unknown. In this study, three human carcinoma cell lines, A549 (lung), HCT116 and COLO205 (colon), were used. The exosome isolation efficiency was compared between three methods: ultracentrifugation, ExoQuick-TC and Total Exosome Isolation kits. Recipient cells were treated with Pitstop 2, an inhibitor of clathrin-dependent endocytosis, or genistein, an inhibitor of caveolae-dependent endocytosis, and then incubated with DiO-labeled exosomes. Among the three methods examined, ultracentrifugation was the most efficient and reproducible. Exosomes derived from a donor cell line are incorporated into the three cell lines, but the exosome uptake capability was different depending on the recipient cell type and did not depend on the donor cell type. Exosome uptake in COLO205 was inhibited by Pitstop 2 and genistein. Exosome uptake in HCT116 was inhibited by Pitstop 2, but not genistein, while that in A549 cells was not inhibited by these inhibitors. Taken together, these results suggest that the exosomes secreted by donor cells are non-selectively incorporated into recipient cells and that the exosome uptake mechanism is different depending on the recipient cells. Different recipient cells’ exosome uptake capabilities may be involved in organ-specific metastasis.
- 1 May 2017
- Published by Elsevier in Biochemical and Biophysical Research Communications
- Vol. 486 (3) , 811-816
Interaction of FAM5C with UDP-glucose:glycoprotein glucosyltransferase 1 (UGGT1): Implication of N -glycosylation in FAM5C secretion
- 1 May 2017
- Published by Elsevier in Biochemical and Biophysical Research Communications
- Vol. 486 (3) , 811-816
Interaction of FAM5C with UDP-glucose:glycoprotein glucosyltransferase 1 (UGGT1): Implication of N -glycosylation in FAM5C secretion
- 14 October 2016
- Published by Wiley in Biopharmaceutics & Drug Disposition
- Vol. 37 (9) , 522-532
Down-regulation of hepatic CYP3A1 expression in a rat model of indomethacin-induced small intestinal ulcers
- 14 October 2016
- Published by Wiley in Biopharmaceutics & Drug Disposition
- Vol. 37 (9) , 522-532
Down-regulation of hepatic CYP3A1 expression in a rat model of indomethacin-induced small intestinal ulcers